# A Multicenter, Single-arm, Prospective Phase II Clinical Study of Epalrotokewali Combined With Eribulin, Anlotinib, and Radiotherapy for the Treatment of Patients With Advanced Soft Tissue Sarcoma.

> **NCT07205185** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Fudan University** · enrollment: 46 (estimated)

## Conditions studied

- Soft Tissue Sarcoma (STS)

## Interventions

- **DRUG:** QL1706 + Eribulin + Anlotinib + Radiotherapy

## Key facts

- **NCT ID:** NCT07205185
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-10-01
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2025-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07205185

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07205185, "A Multicenter, Single-arm, Prospective Phase II Clinical Study of Epalrotokewali Combined With Eribulin, Anlotinib, and Radiotherapy for the Treatment of Patients With Advanced Soft Tissue Sarcoma.". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07205185. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*